Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Standard Care for CMV/BK Prevention in Renal Transplant
NCT04906304Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of everolimus in cytomegalovirus infection (CMV) and BK virus infection (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Cytomegalovirus Infection at 6 months. Started Jan 2020; status: completed.
02
Drugs
everolimus
03
Conditions
cytomegalovirus infection (CMV)BK virus infection
Beyond the preview
Go deeper on NCT04906304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906304.